Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase II study (NCT03580928) investigating a combination of acalabrutinib, venetoclax and obinutuzumab (AVO) as a frontline therapy for chronic lymphocytic leukemia (CLL). The study found that 78% of CLL patients receiving AVO therapy achieved bone marrow undetectable measurable residual disease (MRD) after 15 months of time-limited therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.